[Chronic systolic heart failure - dosing recommendations at beginning and end of treatment]

Ther Umsch. 2008 Oct;65(10):585-92. doi: 10.1024/0040-5930.65.10.585.
[Article in German]

Abstract

As a multi-system disease, chronic heart failure requires a complex, multimodal therapy. Achieving maximum guideline adherence in (advanced) chronic heart failure can therefore become a challenge. The important decrease in morbidity and mortality seen lately largely depends on consequent and sometime tedious implementation of guideline targets. The present paper provides a comprehensive overview on medical therapeutic strategies with a particular focus of onset and discontinuation of drugs in patients with chronic systolic dysfunction.

Publication types

  • English Abstract

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Adrenergic beta-Antagonists / adverse effects
  • Angiotensin II Type 1 Receptor Blockers / administration & dosage
  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Cardiac Glycosides / administration & dosage
  • Cardiac Glycosides / adverse effects
  • Cardiotonic Agents / administration & dosage*
  • Cardiotonic Agents / adverse effects
  • Chronic Disease
  • Diuretics / administration & dosage
  • Diuretics / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Interactions
  • Drug Therapy, Combination
  • Heart Failure / drug therapy*
  • Humans
  • Mineralocorticoid Receptor Antagonists / administration & dosage
  • Mineralocorticoid Receptor Antagonists / adverse effects
  • Systole / drug effects

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Cardiac Glycosides
  • Cardiotonic Agents
  • Diuretics
  • Mineralocorticoid Receptor Antagonists